Innate Pharma S.A.（IPHA）· 损益表

年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。

FMP · IPHA · 截至 2026-06-08

财务报表

Revenue · Gross Profit · Net Income

Breakdown	2025-12	2024-12	2023-12	2022-12	2021-12
Revenue
Revenue	$2.79M	$12.62M	$51.90M	$57.67M	$12.11M
Cost of Revenue	$0.00M	$0.00M	$56.02M	$51.66M	$47.00M
Gross Profit	$2.79M	$12.62M	$5.62M	$6.01M	($22.30M)
Gross Margin %(computed)	100.00%	100.00%	10.83%	10.42%	-184.12%
Operating Expenses
R&D Expenses	$43.62M	$51.98M	$56.02M	$51.66M	$47.00M
G&A Expenses	$11.00M	$11.93M	$11.75M	$14.47M	$15.99M
Total Operating Expenses	$56.21M	$64.20M	$18.29M	$63.44M	$25.52M
Operating Income	($53.42M)	($51.58M)	($12.67M)	($57.42M)	($47.83M)
Operating Margin %(computed)	—	-408.64%	-24.41%	-99.57%	-394.86%
Interest Income	$1.32M	$2.44M	$3.18M	$0.55M	$0.33M
Interest Expense	$0.44M	$0.57M	$0.64M	$0.29M	$0.31M
Income Before Tax	($49.18M)	($49.47M)	($7.57M)	($57.97M)	($45.48M)
Income Tax Expense	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
Net Income	($49.18M)	($49.47M)	($7.57M)	($58.10M)	($52.81M)
Net Margin %(computed)	—	-391.97%	-14.59%	-100.74%	-436.01%
Per Share & EBITDA
EPS (Basic)	$-0.53	$-0.61	$-0.09	$-0.73	$-0.57
Wtd Avg Shares	89.42M	81.05M	84.11M	79.59M	79.54M
EBITDA	($43.65M)	($46.91M)	($1.84M)	($12.28M)	($43.23M)
EBITDA Margin %(computed)	—	-371.69%	-3.54%	-21.29%	-356.91%